Akari Therapeutics plc CEO Gur Roshwalb told BioWorld Today that his firm "like[s] to think we'll be second to market" with once-daily, self-injected therapy Coversin for paroxysmal nocturnal hemoglobinuria (PNH), behind intravenous (I.V.) Soliris (eculizumab, Alexion Pharmaceuticals Inc.), given every other week. Read More
BOGOTA, Colombia – Much of the discussion on the growth of Asian biotech companies is either on their efforts to expand in China or to gain more market share in Europe or North America, but companies are well aware that other markets may also provide interesting opportunities for growth. Read More
HONG KONG – Not only are South Korean biotech companies working their way into the global biosimilars market, they are also tapping the market for gene-based medicines and taking a global leadership role. Read More
BOGOTA, Colombia – As the Argentine biotech sector strengthens on the back of a pivotal leadership shift last year, local companies are looking to tap into international markets, especially countries that lack domestic biopharmaceutical manufacturing. Read More
Andrew Gomperts, president and CEO of Hillhurst Biopharmaceuticals Inc., readily admits the San Diego-based company is "standing on the shoulders of giants" in its quest to translate the potential of five decades of research on the heme oxygenase (HO) pathway into therapeutic agents for sickle cell disease, cerebral injury and other inflammatory conditions such as multiple sclerosis. Read More
Striking back at the growing opioid epidemic in the U.S., the Department of Health and Human Services (HHS) issued a final rule Wednesday to expand access to medication-assisted treatment. Read More
Propanc Health Group Corp., of Melbourne, Australia, said it executed an agreement with an institutional investor resulting in them receiving $314,286 in order to progress their lead product, PRP, toward first-in-human studies. Read More
Knight Therapeutics Inc., of Montreal, and New York-based Ember Therapeutics Inc. amended their exclusive distribution agreement signed in August 2015 to add Romania and the Caribbean to Knight's territorial rights to Ember's Bone Morphogenetic Protein-7 (BMP-7) pipeline. Read More
Anaptysbio Inc., of San Diego, initiated multiple ascending-dose cohorts in an ongoing double-blind, placebo-controlled phase I study of its anti-interleukin-33 antibody, ANB020, in healthy volunteers. Pending full results from the phase I trial, the company plans to develop ANB020 in patients with atopic dermatitis, peanut allergy and asthma. (See BioWorld Today, July 16, 2015.) Read More
